Antagonism of immunostimulatory CpG-oligodeoxynucleotides by 4-aminoquinolines and other weak bases: mechanistic studies.
Oligodeoxynucleotides with unmethylated CpG motifs are immunostimulatory. Chloroquine and a number of structural analogs specifically and powerfully inhibit this effect at nanomolar concentrations. We explored the mechanism of this inhibition, with 4-aminoquinolines, quinacrine, 9-aminoacridines, and novel dibasic analogs, many of which are fluorescent. WEHI 231 murine B-lymphoma cells accumulated analogs up to a concentration several hundredfold higher than the medium. Uptake was rapid, nonsaturable, reversible, and partially inhibited by monensin, an agent that collapses pH gradients within cells. Uptake did not correlate highly with efficacy as inhibitors of CpG-oligodeoxynucleotide (ODN)-induced effects, suggesting that analogs act by a specific action. Confocal microscopy revealed analogs concentrating in large peripheral organelles. CpG-ODN is taken up by cells into acidified, small, perinuclear vesicles. This uptake is thought to be necessary for immunostimulatory activity. Cellular uptake of fluorescent CpG-ODN was not inhibited by the analogs. The pH of intracellular CpG-ODN (6. 4) was not affected by analogs at the concentration required for inhibition, but pH was increased by higher concentrations. UV spectroscopy revealed no binding of analogs to CpG-ODN. Nuclear Overhauser effect spectroscopy revealed that an analog bound to phosphatidylcholine vesicles, with the ring structure of the analog buried within the lipid and the side chain facing the aqueous environment. We conclude that the analogs do not inhibit the action of CpG-ODN by preventing the uptake or acidification of CpG-ODN. It seems more likely that the analogs inhibit the efficacy of CpG-ODN by a specific action within acidified vesicles, possibly at the interface of a phospholipid membrane.
Manzel
L
L
Department of Medicine, Veterans Affairs Medical Center and University of Iowa, Iowa City, Iowa 52242, USA.
Strekowski
L
L
Ismail
F M
FM
Smith
J C
JC
Macfarlane
D E
DE
D000276:Adjuvants, Immunologic / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D000468:Alkalies / Q000494:pharmacology; D000634:Aminoquinolines / Q000494:pharmacology*; D018899:CpG Islands; D004277:DNA, Single-Stranded / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D007476:Ionophores / Q000494:pharmacology; D008055:Lipids / Q000737:chemistry; D009682:Magnetic Resonance Spectroscopy; D008567:Membranes, Artificial; D018613:Microscopy, Confocal; D008985:Monensin / Q000494:pharmacology; D009841:Oligonucleotides / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology; D010743:Phospholipids / Q000737:chemistry; D013347:Subcellular Fractions / Q000187:drug effects / Q000378:metabolism; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; D000468:Alkalies; D000634:Aminoquinolines; D004277:DNA, Single-Stranded; D007476:Ionophores; D008055:Lipids; D008567:Membranes, Artificial; D009841:Oligonucleotides; D010743:Phospholipids; D008985:Monensin